Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosis.

van Egmond E, van Gorp D, Honan C, Heerings M, Jongen P, van der Klink J, Reneman M, Beenakker E, Frequin S, de Gans K, Hengstman G, Hoitsma E, Mostert J, Verhagen W, Zemel D, Middelkoop H, Visser L, van der Hiele K.

Disabil Rehabil. 2019 Nov 8:1-10. doi: 10.1080/09638288.2019.1686072. [Epub ahead of print]

PMID:
31702954
2.

Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.

van Gorp DAM, van der Hiele K, Heerings MAP, Jongen PJ, van der Klink JJL, Reneman MF, Arnoldus EPJ, Beenakker EAC, van Eijk JJJ, Frequin STFM, de Gans K, Hoitsma E, Mostert JP, Verhagen WIM, Zemel D, Visser LH, Middelkoop HAM.

Neurol Sci. 2019 Dec;40(12):2555-2564. doi: 10.1007/s10072-019-03999-w. Epub 2019 Jul 19.

3.

Subacute Combined Spinal Cord Degeneration by Recreational Laughing Gas (N2O) Use.

Onrust MR, Frequin ST.

J Cent Nerv Syst Dis. 2019 Mar 26;11:1179573519838277. doi: 10.1177/1179573519838277. eCollection 2019.

4.

Caregiver strain among life partners of persons with mild disability due to relapsing-remitting multiple sclerosis.

van der Hiele K, van Gorp DAM, Heerings MAP, Jongen PJ, van der Klink JJL, Beenakker EAC, van Eijk JJJ, Frequin STFM, van Geel BM, Hengstman GJD, Hoitsma E, Mostert JP, Verhagen WIM, de Gans K, Zemel D, Middelkoop HAM, Visser LH.

Mult Scler Relat Disord. 2019 Jun;31:5-11. doi: 10.1016/j.msard.2019.03.005. Epub 2019 Mar 6.

5.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.

Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.

J Med Econ. 2018 Oct;21(10):968-976. doi: 10.1080/13696998.2018.1489255. Epub 2018 Jul 9.

PMID:
29911917
6.

The capability set for work - correlates of sustainable employability in workers with multiple sclerosis.

van Gorp DAM, van der Klink JJL, Abma FI, Jongen PJ, van Lieshout I, Arnoldus EPJ, Beenakker EAC, Bos HM, van Eijk JJJ, Fermont J, Frequin STFM, de Gans K, Hengstman GJD, Hupperts RMM, Mostert JP, Pop PHM, Verhagen WIM, Zemel D, Heerings MAP, Reneman MF, Middelkoop HAM, Visser LH, van der Hiele K.

Health Qual Life Outcomes. 2018 Jun 1;16(1):113. doi: 10.1186/s12955-018-0942-7.

7.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
8.

Coping strategies in relation to negative work events and accommodations in employed multiple sclerosis patients.

van der Hiele K, van Gorp D, Benedict R, Jongen PJ, Arnoldus E, Beenakker E, Bos HM, van Eijk J, Fermont J, Frequin S, van Geel BM, Hengstman G, Hoitsma E, Hupperts R, Mostert JP, Pop P, Verhagen W, Zemel D, Frndak SE, Heerings M, Middelkoop H, Visser LH.

Mult Scler J Exp Transl Clin. 2016 Nov 24;2:2055217316680638. doi: 10.1177/2055217316680638. eCollection 2016 Jan-Dec.

9.

Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression.

Hagens MH, Hoogervorst EL, Frequin ST, Tromp SC.

Interv Neurol. 2014 Aug;2(4):193-200. doi: 10.1159/000363070.

10.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9.

PMID:
25205744
11.

Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.

Jongen PJ, Lehnick D, Koeman J, Frequin S, Heersema D, Kornips B, Schyns-Soeterboek A, Visser LH, Schiphof P, Valkenburg A, Hiel J; FOCUS Extension Study Group.

J Neurol. 2014 Aug;261(8):1469-76. doi: 10.1007/s00415-014-7363-2. Epub 2014 May 3.

12.

[A woman with a postoperative lumbar swelling].

Hulshof HM, Elsenburg PH, Frequin ST.

Ned Tijdschr Geneeskd. 2013;157(19):A6119. Dutch.

PMID:
23657102
13.

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.

Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG.

J Med Econ. 2012;15(6):1149-58. doi: 10.3111/13696998.2012.707631. Epub 2012 Jul 27.

PMID:
22737996
14.

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice.

Jongen PJ, Sindic C, Sanders E, Hawkins S, Linssen W, van Munster E, Frequin S, Borm G; Functional Composite and Quality of Life in Avonex-treated Relapsing Multiple Sclerosis Patients Study Group.

PLoS One. 2011;6(10):e26568. doi: 10.1371/journal.pone.0026568. Epub 2011 Oct 25.

15.

[Prognosis for patients in a coma following cardiopulmonary resuscitation].

Kranenborg H, Meinders AJ, Frequin ST, Teunissen LL, Mauser HW, Vogels OJ.

Ned Tijdschr Geneeskd. 2008 May 31;152(22):1296-7; author reply 1297. Dutch. No abstract available.

PMID:
18590066
16.

Daily negative interactions and mood among patients and partners dealing with multiple sclerosis (MS): the moderating effects of emotional support.

Kleiboer AM, Kuijer RG, Hox JJ, Jongen PJ, Frequin ST, Bensing JM.

Soc Sci Med. 2007 Jan;64(2):389-400. Epub 2006 Sep 29.

PMID:
17011095
17.

Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study.

van Walderveen MA, Barkhof F, Tas MW, Polman C, Frequin ST, Hommes OR, Thompson AJ, Valk J.

Eur Neurol. 1998 Aug;40(2):91-8.

PMID:
9693238
18.

Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials.

Truyen L, Barkhof F, Tas M, Van Walderveen MA, Frequin ST, Hommes OR, Nauta JJ, Polman CH, Valk J.

Mult Scler. 1997 Jan;2(6):283-90.

PMID:
9065919
19.

Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future.

Hommes OR, Barkhof F, Jongen PJ, Frequin ST.

Mult Scler. 1996 Jul;1(6):327-8. Review.

PMID:
9345410
20.

Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine.

Truyen L, Barkhof F, Frequin ST, Polman CH, Tobi H, Hommes OR, Valk J.

Mult Scler. 1996 Feb;1(4):213-7.

PMID:
9345437
21.

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.

van Walderveen MA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin ST, Valk J.

Neurology. 1995 Sep;45(9):1684-90.

PMID:
7675227
22.

Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.

Frequin ST, Lamers KJ, Barkhof F, Borm GF, Hommes OR.

Acta Neurol Scand. 1994 Aug;90(2):105-10.

PMID:
7801735
23.

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

Barkhof F, Tas MW, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, Valk J.

Neuroradiology. 1994 Jul;36(5):382-7.

PMID:
7936181
24.

Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.

van Walderveen MA, Tas MW, Barkhof F, Polman CH, Frequin ST, Hommes OR, Valk J.

Neurology. 1994 Feb;44(2):327-9.

PMID:
8309584
25.

T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

Frequin ST, Lamers KJ, Borm GF, Barkhof F, Jongen PJ, Hommes OR.

Acta Neurol Scand. 1993 Aug;88(2):80-6.

PMID:
8213063
26.
27.

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J, Hommes OR.

AJR Am J Roentgenol. 1992 Nov;159(5):1041-7.

PMID:
1414773
28.
29.

CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone.

Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF.

Acta Neurol Scand. 1992 Sep;86(3):291-7.

PMID:
1384263
30.

[Multiple sclerosis].

Frequin ST, Hommes OR.

Ned Tijdschr Tandheelkd. 1992 Feb;99(2):46-8. Review. Dutch. No abstract available.

PMID:
11819990
31.

A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

Barkhof F, Frequin ST, Hommes OR, Lamers K, Scheltens P, van Geel WJ, Valk J.

Neurology. 1992 Jan;42(1):63-7.

PMID:
1370864
32.

Recurrent prolonged coma due to basilar artery migraine. A case report.

Frequin ST, Linssen WH, Pasman JW, Hommes OR, Merx HL.

Headache. 1991 Feb;31(2):75-81.

PMID:
2030077
33.

Sensory axonopathy in hereditary distal spinal muscular atrophy.

Frequin ST, Gabreëls FJ, Gabreëls-Festen AA, Joosten EM.

Clin Neurol Neurosurg. 1991;93(4):323-6.

PMID:
1665767

Supplemental Content

Loading ...
Support Center